基于VOSviewer的甲状腺癌分子与细胞生物学领域的可视化分析

doi:10.11958/20231667

天津医药 ›› 2024, Vol. 52 ›› Issue (9): 985-990.doi: 10.11958/20231667

基于VOSviewer的甲状腺癌分子与细胞生物学领域的可视化分析

丁培森¹(), 刘思雨¹, 邢志磊¹, 于晓猛², 宋佳慧¹, 崔玉山³, 刘洪亮¹^,^△()

1 天津医科大学公共卫生学院（邮编300070）
2 天津市医药科学研究所
3 天津市疾病预防控制中心环境健康与学校卫生研究所

收稿日期:2023-11-01 修回日期:2024-01-11 出版日期:2024-09-15 发布日期:2024-09-06
通讯作者: ^△E-mail：hongliang_liu@sina.com
作者简介:丁培森(1997)，男，硕士在读，主要从事碘对人体健康影响方面研究。E-mail：1714277991@qq.com
基金资助:
国家自然科学基金资助项目(82173641);环境与健康教育部重点实验室开放课题(2021GWKFJJ03)

Visual analysis of molecular and cellular biology of thyroid cancer based on VOSviewer

DING Peisen¹(), LIU Siyu¹, XING Zhilei¹, YU Xiaomeng², SONG Jiahui¹, CUI Yushan³, LIU Hongliang¹^,^△()

1 SchooI of Public Health, Tianjin Medical University, Tianjin 300070, China
2 Tianjin Institute of Pharmaceutical Science
3 Institute of Environmental Health and School Health, Tianjin Center for Disease Control and Prevention

Received:2023-11-01 Revised:2024-01-11 Published:2024-09-15 Online:2024-09-06
Contact: ^△E-mail：hongliang_liu@sina.com

丁培森, 刘思雨, 邢志磊, 于晓猛, 宋佳慧, 崔玉山, 刘洪亮. 基于VOSviewer的甲状腺癌分子与细胞生物学领域的可视化分析[J]. 天津医药, 2024, 52(9): 985-990.

DING Peisen, LIU Siyu, XING Zhilei, YU Xiaomeng, SONG Jiahui, CUI Yushan, LIU Hongliang. Visual analysis of molecular and cellular biology of thyroid cancer based on VOSviewer[J]. Tianjin Medical Journal, 2024, 52(9): 985-990.

摘要/Abstract

摘要：

目的了解甲状腺癌分子与细胞生物学领域的研究现状与发展趋势。方法在科学网核心合集（WoSCC）中按照检索条件获取甲状腺癌分子与细胞生物学领域2013年1月1日—2022年12月31日发表的相关文献，利用文献计量软件VOSviewer和Excel进行文献计量与可视化分析。结果共纳入文献1 627篇，其中2013年发文量为113篇，2022年发文量为214篇，年度发文量总体呈上升趋势。共有9 274名作者，其中发文量不低于10篇的有6名。共有2 042个机构，其中发文量前10的机构大多是中国的大学。共有68个国家，发文量最大的国家是中国，其次是美国。共有513种期刊，载文量前10的期刊主要是肿瘤学领域期刊，其次是内分泌与代谢领域期刊。共引用了5 887种期刊的62 563篇文献，共被引次数最高的期刊是《Journal of Biological Chemistry》（1 608次），共被引用次数最高的文献是《Molecular pathogenesis and mechanisms of thyroid cancer》（89次）。结论甲状腺癌分子与细胞生物学领域目前正在稳步发展，铁死亡、糖基化、端粒酶逆转录酶以及氧化应激是该领域的研究前沿。

关键词: 甲状腺肿瘤, 文献计量学, 电子数据处理, 信号传导, VOSviewer

Abstract:

Objective To understand the research status and development trend in the field of molecular and cell biology of thyroid cancer. Methods Relevant literature published in the field of molecular and cell biology of thyroid cancer from January 1, 2013 to December 31, 2022 was obtained in the web of science core collection (WoSCC) according to the search conditions, and bibliometric and visual analysis were performed using the bibliometric software VOSviewer and Excel. Results A total of 1 627 literatures were included. Among them, 113 papers were published in 2013, and 214 were published in 2022. The annual number of publications was on the rise. There were 9 274 authors in total, of whom 6 published no less than 10 literatures. There were a total of 2 042 institutions, of which the top 10 institutions were mostly Chinese universities. There were 68 countries in total, and the largest number of publications was China, followed by the United States. There were 513 journals in total, and the top 10 journals with the largest number of literatures were mainly in the field of oncology, followed by the field of endocrinology and metabolism. A total of 62 563 references from 5 887 journals were cited. The most co-cited journal was Journal of Biological Chemistry (1 608 times), and the most co-cited references was Molecular Pathogenesis and Mechanisms of Thyroid Cancer (89 times). Conclusion The field of molecular and cell biology of thyroid cancer is currently developing steadily. Ferroptosis, glycosylation, telomerase reverse transcriptase and oxidative stress are the research frontiers in this field.

Key words: thyroid neoplasms, bibliometrics, electronic data processing, signal transduction, VOSviewer

中图分类号:

R736.1，G353.1

图/表 9

图1 文献筛选流程

Fig.1 Literature screening flow

图2 2013—2022年相关文献发文量变化

Fig.2 Changes in documents related during 2013-2022

表1 2013—2022年发（载）文量前10的作者、机构、期刊

Tab.1 Authors, institutions and journals of the top 10 publications during 2013-2022

序号	作者				机构				期刊
序号	姓名	被引量/次	发文量/篇	篇均被引量/次	机构名	被引量/ 次	发文量/篇	篇均被引量/次	期刊名	被引量/次	载文量/ 篇	篇均被引量/次
1	ENG C	353	10	35.3	中国医科大学	832	38	14.1	Oncotarget	1 279	62	20.6
2	FUSCO A	290	11	26.4	复旦大学	786	41	19.2	International Journal of Molecular Sciences	705	35	12.1
3	ZHANG L	202	13	15.5	美国国家癌症研究所	620	44	21.9	Oncology Letters	580	30	9.3
4	HOU P	202	11	18.4	上海交通大学	554	26	9.1	Cancers	508	42	20.1
5	RUSSO D	172	9	19.1	西安交通大学	466	23	13.6	Endocrine-related Cancer	436	24	19.3
6	CHENG S P	155	10	15.5	那不勒斯费德里科二世大学	395	29	21.3	Frontiers in Oncology	392	20	9.7
7	QU N	154	10	15.4	纪念斯隆-凯特琳癌症中心	365	23	15.9	Endocrine	361	22	13.1
8	WANG Y	105	9	11.7	中山大学	310	34	20.3	Tumor Biology	336	36	18.2
9	LIU W	100	9	11.1	山东大学	304	21	14.5	Oncology Reports	327	25	16.4
10	CHENG S Y	76	8	9.5	温州医科大学	178	21	8.5	Frontiers in Endocrinology	282	29	19.6

表2 2013—2022年发文量排名前6位国家及其发文量与文章被引情况

Tab.2 The top 6 countries ranked and the number of articles and articles cited during 2013-2022

序号	国家	发文量/篇	被引量/次	篇均被引量/次
1	中国	667	8 081	12.1
2	美国	291	6 470	22.2
3	意大利	155	3 089	19.9
4	韩国	95	1 115	11.7
5	日本	78	1 108	14.2
6	德国	76	1 562	20.6

图3 2013—2022年关键词共现网络关键词节点越大，代表关键词出现的频率越高，节点间的连线越粗，代表2个关键词之间的关联强度越大。绿色：甲状腺癌聚类；红色：乳头状甲状腺癌聚类；黄色：放射性治疗聚类；橙色：生物标志物聚类；紫色：甲状腺聚类；深蓝色：表观遗传学聚类；浅蓝色：凋亡与自噬聚类；褐色：YAP聚类。

Fig.3 Keyword co-occurrence network of 2013-2022

图4 2013—2022年关键词共现随时间变化关键词节点越大，代表关键词出现的频率越高。黄色节点代表近年来新出现的关键词，绿色节点代表出现时间较早的关键词，节点颜色由深蓝向浅黄色的过渡反映2013—2022年关键词随时间的变化趋势。

Fig.4 Co-occurrence of keywords changed over time during 2013-2022

图5 2013—2022年共被引大于300次的50种期刊节点越大，表示期刊共被引的次数越多。红色：医学肿瘤学领域；蓝色：临床应用领域；黄色：内分泌与代谢领域；绿色：医学综合领域。

Fig.5 Fifty journals with more than 300 co-citations during 2013-2022

图6 2013—2022年共被引大于20次的51篇文献节点越大，表示文献共被引的次数越多。红色：甲状腺癌流行病学聚类；黄色：肿瘤代谢聚类；蓝色：上皮间质转化聚类；绿色：TERT启动子突变聚类；紫色：PTEN错构瘤聚类。

Fig.6 Fifty-one articles cited more than 20 times during 2013-2022

表3 2013—2022年总共被引数前5的文献

Tab.3 The top 5 co-cited references during 2013-2022

序号	题目	作者	共被引数	发表年	期刊
1	Molecular pathogenesis and mechanisms of thyroid cancer	XING Mingzhao	89	2013	Nature Reviews Cancer
2	2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer	HAUGEN Bryan R	71	2016	Thyroid
3	Integrated genomic characterization of papillary thyroid carcinoma	AGRAWAL Nishant	67	2014	Cell
4	Hallmarks of cancer： the next generation	HANAHAN Douglas	60	2011	Cell
5	Thyroid cancer	CABANILLAS Maria E	58	2016	The Lancet

参考文献 30

[1]	LIM H, DEVESA S S, SOSA J A, et al. Trends in thyroid cancer incidence and mortality in the United States,1974-2013[J]. JAMA, 2017, 317(13):1338-1348. doi:10.1001/jama.2017.2719.
[2]	董芬, 张彪, 单广良. 中国甲状腺癌的流行现状和影响因素[J]. 中国癌症杂志, 2016(1):47-52.
	DONG F, ZHANG B, SHAN G L. Distribution and risk factors of thyroid cancer in China[J]. China Oncol, 2016(1):47-52. doi:10.3969/j.issn.1007-3969.2016.01.008.
[3]	ENEWOLD L, ZHU K, RON E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics,1980-2005[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(3):784-791. doi:10.1158/1055-9965.EPI-08-0960.
[4]	XING M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3):184-199. doi:10.1038/nrc3431.
[5]	QIN Y, ZHANG Q, LIU Y. Analysis of knowledge bases and research focuses of cerebral ischemia-reperfusion from the perspective of mapping knowledge domain[J]. Brain Res Bull, 2020, 156:15-24. doi:10.1016/j.brainresbull.2019.12.004.
[6]	唐增煦, 高凌, 崔彦红, 等. 《卫生研究》2011—2020年高被引论文特征分析[J]. 卫生研究, 2023, 52(5):774-776.
	TANG Z X, GAO L, CUI Y H, et al. Analysis of the characteristics of highly cited papers in Health Research from 2011 to 2020[J]. J Hyg Res, 2023, 52(5):774-776. doi:10.19813/j.cnki.weishengyanjiu.2023.05.014.
[7]	SHEN W H, BALAJEE A S, WANG J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity[J]. Cell, 2007, 128(1):157-170. doi:10.1016/j.cell.2006.11.042.
[8]	TAN M H, MESTER J, PETERSON C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands[J]. Am J Hum Genet, 2011, 88(1):42-56. doi:10.1016/j.ajhg.2010.11.013.
[9]	XU D, GUO L, ZHANG S, et al. LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the PI3K/AKT pathway[J]. Gland Surg, 2022, 11(9):1518-1528. doi:10.21037/gs-22-452.
[10]	CHEN B, LEI S, YIN X, et al. Mitochondrial respiration inhibition suppresses papillary thyroid carcinoma via PI3K/Akt/FoxO1/Cyclin D1 pathway[J]. Front Oncol, 2022,12:900444. doi:10.3389/fonc.2022.900444.
[11]	BARÉS G, BEÀ A, HERNÁNDEZ L, et al. ENDOG impacts on tumor cell proliferation and tumor prognosis in the context of PI3K/PTEN pathway status[J]. Cancers (Basel), 2021, 13(15):3803. doi:10.3390/cancers13153803.
[12]	ZHANG W, RUAN X, LI Y, et al. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway[J]. Theranostics, 2022, 12(4):1500-1517. doi:10.7150/thno.66142.
[13]	THANAS C, ZIROS P G, CHARTOUMPEKIS D V, et al. The Keap1/Nrf2 signaling pathway in the thyroid-2020 update[J]. Antioxidants (Basel), 2020, 9(11):1082. doi:10.3390/antiox9111082.
[14]	FOTH M, MCMAHON M. Autophagy inhibition in BRAF-driven cancers[J]. Cancers (Basel), 2021, 13(14):3498. doi:10.3390/cancers13143498.
[15]	PRATT E C, ISAAC E, STATER E P, et al. Synthesis of the PET tracer (124)I-trametinib for MAPK/ERK kinase distribution and resistance monitoring[J]. J Nucl Med, 2020, 61(12):1845-1850. doi:10.2967/jnumed.120.241901.
[16]	PIANA S, ZANETTI E, BISAGNI A, et al. Expression of NOTCH1 in thyroid cancer is mostly restricted to papillary carcinoma[J]. Endocr Connect, 2019, 8(8):1089-1096. doi:10.1530/EC-19-0303.
[17]	KIM H J, KIM M J, KIM A, et al. The role of Notch1 signaling in anaplastic thyroid carcinoma[J]. Cancer Res Treat, 2017, 49(2):509-517. doi:10.4143/crt.2016.214.
[18]	崔玉山, 刘洪亮. 甲状腺癌流行病学特征和碘营养关系研究进展[J]. 环境卫生学杂志, 2020, 10(2):212-217.
	CUI Y S, LIU H L. Epidemiological characteristics of thyroid cancer and its association with iodine nutrition[J]. J Environ Hyg, 2020, 10(2):212-217. doi:10.13421/j.cnki.hjwsxzz.2020.02.023.
[19]	杨绍时, 周扬, 柴慈曼, 等. 甲状腺微小乳头状癌组织学亚型的临床病理意义及与颈部淋巴结转移的关系[J]. 天津医药, 2022, 50(6):638-642.
	YANG S S, ZHOU Y, CHAI C M, et al. Clinicopathological significance of histological subtypes in papillary thyroid microcarcinoma and its correlation with cervical lymph node metastasis[J]. Tianjin Med J, 2022, 50(6):638-642. doi:10.11958/20211096.
[20]	DONALDSON L B, YAN F, MORGAN P F, et al. Hobnail variant of papillary thyroid carcinoma: a systematic review and Meta-analysis[J]. Endocrine, 2021, 72(1):27-39. doi:10.1007/s12020-020-02505-z.
[21]	SCHONFELD S J, MORTON L M, BERRINGTON DE GONZÁLEZ A, et al. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States,2000-2015[J]. Cancer Epidemiol, 2020,64:101664. doi:10.1016/j.canep.2019.101664.
[22]	JOSEPH K R, EDIRIMANNE S, ESLICK G D. The association between breast cancer and thyroid cancer: a Meta-analysis[J]. Breast Cancer Res Treat, 2015, 152(1):173-181. doi:10.1007/s10549-015-3456-6.
[23]	MESTER J, CHARIS E. PTEN hamartoma tumor syndrome[J]. Handb Clin Neurol, 2015,132:129-137. doi:10.1016/B978-0-444-62702-5.00009-3.
[24]	WANG X, XU S, ZHANG L, et al. Vitamin C induces ferroptosis in anaplastic thyroid cancer cells by ferritinophagy activation[J]. Biochem Biophys Res Commun, 2021, 551:46-53. doi:10.1016/j.bbrc.2021.02.126.
[25]	QIN Y, ZHANG D, ZHANG H, et al. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma[J]. Cancer Cell Int, 2022, 22(1):296. doi:10.1186/s12935-022-02674-z.
[26]	REN X, DU H, CHENG W, et al. Construction of a ferroptosis-related eight gene signature for predicting the prognosis and immune infiltration of thyroid cancer[J]. Front Endocrinol (Lausanne), 2022,13:997873. doi:10.3389/fendo.2022.997873.
[27]	SHI J, WU P, SHENG L, et al. Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma[J]. Cancer Cell Int, 2021, 21(1):669. doi:10.1186/s12935-021-02389-7.
[28]	KUDELKA M R, LASANAJAK Y, SMITH D F, et al. Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer[J]. Cancer Med, 2023, 12(6):6768-6777. doi:10.1002/cam4.5465.
[29]	REN X, SHU J, WANG J, et al. Machine learning reveals salivary glycopatterns as potential biomarkers for the diagnosis and prognosis of papillary thyroid cancer[J]. Int J Biol Macromol, 2022, 215:280-289. doi:10.1016/j.ijbiomac.2022.05.194.
[30]	COBO M J, LÓPEZ-HERRERA A G, HERRERA-VIEDMA E, et al. Science mapping software tools:review,analysis,and cooperative study among tools[J]. JASIST, 2011, 62(7):1382-1402. doi:10.1002/ASI.21525.

基于VOSviewer的甲状腺癌分子与细胞生物学领域的可视化分析

Visual analysis of molecular and cellular biology of thyroid cancer based on VOSviewer

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 9

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘青青, 李宜蔷, 石玉士, 陆海颂, 程纬民. TGF-β信号通路在骨髓增生异常综合征中作用机制的研究进展[J]. 天津医药, 2024, 52(7): 781-784.
[2]	郑君毅, 李晓凤, 郭绪昆. 褪黑素对心肌缺血再灌注损伤的保护作用及机制[J]. 天津医药, 2023, 51(10): 1054-1058.
[3]	杨绍时, 周扬, 柴慈曼, 孙宁, 王宏, 孙宇△. 甲状腺微小乳头状癌组织学亚型的临床病理意义及与颈部淋巴结转移的关系[J]. 天津医药, 2022, 50(6): 638-642.
[4]	程冉, 魏枫△, 张苑, 刘美岚, 贺佳. 5-氮杂-2′-脱氧胞苷对人甲状腺癌裸鼠移植瘤的抑制作用及其机制的研究#br#[J]. 天津医药, 2022, 50(5): 476-481.
[5]	王琼, 詹江华△. 瘦素对肝星状细胞活化的调控及其在肝纤维化进展中的作用[J]. 天津医药, 2022, 50(1): 25-29.
[6]	许卫国, 全江涛, 周娟, 张智林, 廖扬, 陈蕊. miR-155联合超声对分化型甲状腺癌淋巴结转移的诊断价值分析[J]. 天津医药, 2021, 49(7): 731-735.
[7]	李丽华, 王玉娇, 李俊雄, 李思玉, 唐婉容, 邱亚. 白藜芦醇抑制人牙龈成纤维细胞炎症和氧化应激的机制研究[J]. 天津医药, 2021, 49(12): 1245-1249.
[8]	陆海永, 李朝喜, 温德惠△, 王义成. 多模态超声在中、高度可疑恶性甲状腺结节鉴别中的诊断价值#br#[J]. 天津医药, 2021, 49(1): 69-73.
[9]	吴小寒, 刘长乐. NLRP3炎症小体与心房颤动的研究进展[J]. 天津医药, 2019, 47(3): 329-332.
[10]	陈建梅, 杨蕊蕊, 刘洪恩, 刘洪欣, 史文新, 刘姣. JAK2/STAT3信号转导通路在子宫内膜异位症发病过程中的作用[J]. 天津医药, 2019, 47(2): 136-139.
[11]	石武娟, 薛珊珊. 常染色体隐性遗传性皮肤松弛症的相关基因研究进展[J]. 天津医药, 2018, 46(9): 1027-1032.
[12]	卞敬琦，冯月男，牛雯颖，肖洪彬△. 血小板活化信号转导机制研究进展[J]. 天津医药, 2018, 46(1): 99-103.
[13]	贾强, 张春梅, 孟召伟, 谭建. 血清 midkine 对甲状腺球蛋白抗体阳性甲状腺癌患者转移病灶的预测价值[J]. 天津医药, 2017, 45(7): 739-741.
[14]	郝伟静 1，于洋 1，王青松 2，赵丽 3，叶艳 4，董莉 1，李健森 5，孟祥睿 5，运新伟 1，高明 1. MLH1 R217C/BRAF V600E 突变型家族性甲状腺乳头状癌永生化细胞系的建立及鉴定[J]. 天津医药, 2016, 44(6): 657-661.
[15]	侯卫东1,王俊宏1△，张志宇1,李进1,刘艳晓1,丁红霞1,禹远远1,田勇1,刘艳峰2. 甲状腺乳头状癌中CA19-9、 CA15-3 和 CA125的表达及意义[J]. 天津医药, 2016, 44(12): 1496-1499.